India, May 19 -- 23andMe Holding Co. (MEHCQ) surged 163.33 percent to $2.37 on Monday after announcing a definitive agreement to sell substantially all of its assets to Regeneron Pharmaceuticals for $256 million.
The stock opened at $1.71 and traded between $1.67 and $2.52 on the OTC Markets. Volume reached 1.11 million shares, below the average of 4.08 million. MEHCQ now trades within a 52-week range of $0.47 to $12.32.
The deal includes 23andMe's Personal Genome Service, Total Health, and Research Services business lines but excludes its Lemonaid Health subsidiary, which will be wound down.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....